From The Economic Times · · 40s
RanluspecTM EU Approval for Retinal Disease Treatment
Lupin's biosimilar RanluspecTM launches across Europe for retinal disease treatment after EU approval.
In brief
Lupin's biosimilar RanluspecTM launches across Europe for retinal disease treatment after EU approval. Lupin and Sandoz launch RanluspecTM, a biosimilar of Ranibizumab, across Europe for retinal diseases after European Commission approval. Originally reported by The Economic Times.
EU Approval for RanluspecTM
Lupin's commercial partner Sandoz receives EU Commission approval for RanluspecTM biosimilar of Ranibizumab.
“The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases”
RanluspecTM Treatment Indications
RanluspecTM treats neovascular age-related macular degeneration, macular edema, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.
“Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A”
RanluspecTM Launch Across Europe
Lupin and Sandoz launch RanluspecTM across Europe excluding Germany for retinal disease treatment.
“Together with Sandoz, we will expand access to this important treatment across the region”
What matters most
Lupin and Sandoz launch RanluspecTM, a biosimilar of Ranibizumab, across Europe for retinal diseases after European Commission approval.
